Related references
Note: Only part of the references are listed.Efficacy of rituximab in refractory neuromyelitis optica
N. Collongues et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients
M. Radaelli et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Efficacy of rituximab in refractory neuromyelitis optica
N. Collongues et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients
M. Radaelli et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study
Pietro Annovazzi et al.
JOURNAL OF NEUROLOGY (2016)
Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders A Systematic Review and Meta-analysis
Valentina Damato et al.
JAMA NEUROLOGY (2016)
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
Dean M. Wingerchuk et al.
NEUROLOGY (2015)
Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder
Marius Ringelstein et al.
JAMA NEUROLOGY (2015)
Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab
Manabu Araki et al.
Modern Rheumatology (2014)
Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica A pilot study
Manabu Araki et al.
NEUROLOGY (2014)
Disease Amelioration With Tocilizumab in a Treatment-Resistant Patient With Neuromyelitis Optica Implication for Cellular Immune Responses
Bernd C. Kieseier et al.
JAMA NEUROLOGY (2013)
Interleukin 6 Receptor Blockade in Patients With Neuromyelitis Optica Nonresponsive to Anti-CD20 Therapy
Ilya Ayzenberg et al.
JAMA NEUROLOGY (2013)
A 5-Year Follow-up of Rituximab Treatment in Patients With Neuromyelitis Optica Spectrum Disorder
Su-Hyun Kim et al.
JAMA NEUROLOGY (2013)
Failure of Natalizumab to Prevent Relapses in Neuromyelitis Optica
Ingo Kleiter et al.
ARCHIVES OF NEUROLOGY (2012)
Repeated Treatment With Rituximab Based on the Assessment of Peripheral Circulating Memory B Cells in Patients With Relapsing Neuromyelitis Optica Over 2 Years
Su-Hyun Kim et al.
ARCHIVES OF NEUROLOGY (2011)
Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab
H. L. Pellkofer et al.
NEUROLOGY (2011)
Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica
Norio Chihara et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Enhanced IL-6 Production in Aquaporin-4 Antibody Positive Neuromyelitis Optica Patients
Sema Icoz et al.
INTERNATIONAL JOURNAL OF NEUROSCIENCE (2010)
Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6
Akiyuki Uzawa et al.
MULTIPLE SCLEROSIS JOURNAL (2010)
Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis
Akiyuki Uzawa et al.
JOURNAL OF NEUROLOGY (2009)
Treatment of Neuromyelitis Optica With Rituximab Retrospective Analysis of 25 Patients
Anu Jacob et al.
ARCHIVES OF NEUROLOGY (2008)
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
Josef S. Smolen et al.
LANCET (2008)
Review: Treatment of neuromyelitis optica: Current debate
Tomoko Okamoto et al.
Therapeutic Advances in Neurological Disorders (2008)
Clinical characteristics, course and prognosis of relapsing Devic's Neuromyelitis Optica
A Ghezzi et al.
JOURNAL OF NEUROLOGY (2004)
Share Paper
